Asia-Pacific Conference, Beijing, 2014; 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, 2014 Patent Zhi Qu. 2013. Sensitive question investigating device. CN
decision support and digital health applications “discriminate” in order to mark diagnostic and therapeutic pathways without pointing in undesirable directions and possibly excluding people in the process
topics within larger research projects, both in the basic scientific as well as in the clinical-therapeutic area. In addition, there is occasionally the opportunity to make the evaluation of existing data
MJ, Manns MP, Ott M: Regional and transient ischemia/reperfusion injury in the liver improves therapeutic efficacy of allogeneic intraportal hepatocyte transplantation in low-density lipoprotein receptor
Seeliger B, Schmidt JJ, Wiesner O, Schmidt BMW, Taubert R, Vondran FWR , Hoeper MM, David S. Therapeutic plasma exchange in acute on chronic liver failure. J Clin Apher. 2020 Jun 24. doi: 10.1002/jca
Seeliger B, Schmidt JJ, Wiesner O, Schmidt BMW, Taubert R, Vondran FWR , Hoeper MM, David S. Therapeutic plasma exchange in acute on chronic liver failure. J Clin Apher. 2020 Jun 24. doi: 10.1002/jca
12:00 Uhr 14.06.2024 Khadija Aichane „Engineering the adenovirus E3/49K protein for potential therapeutic applications“ Gebäude I3, Ebene 01, Raum 2020 Beginn: 12:00 Uhr 31.05.2024 Dr. Alexandra Koch "A [...] Ebene 01, Raum 2020 Beginn: 12:00 Uhr 26.05.2023 Präsenzveranstaltung Dr. Mark Windheim "Potential therapeutic application of the immunomodulatory adenovirus E3/49K protein" Gebäude I3, Ebene 01, Raum 2020 [...] 2020 Beginn: 12:00 Uhr 05.05.2023 Präsenzveranstaltung Prof. Dr. Christian Bär "Telomerase as therapeutic target in cardiac protection and regeneration" Gebäude I3, Ebene 01, Raum 2020 Beginn: 12:00 Uhr 21
addition, we are constantly conducting a large number of scientific studies on clinical aspects, new therapeutic approaches and the causes of Tourette syndrome. Under the direction of Prof. Kirsten R. Müller-Vahl
after the return to work to provide a long-term support. The implemented concept links medical-therapeutic treatment with corporate actions to reinforce the job-related reintegration. The project will be
g of the underlying biology of acute myeloid leukemia (AML), treatment of AML remains a major therapeutic challenge with long-term survival under 30%. Responsible for this are residual leukemic stem cells